LP Pharmaceutical

About LP Pharmaceutical

LP Pharmaceutical is a drug development company established in 2012, headquartered in Xiamen, China. The firm focuses on creating modified new drugs by leveraging its proprietary drug delivery technology platforms, which include innovative oral mucosal drug delivery, gas microspheres, and controlled-release formulations. Its business model centers on developing pharmaceuticals with high technical barriers to address unmet clinical needs, aiming to provide safer and more effective treatment options.

The company was founded by Dr. Ying Ye (叶英), who serves as the chairwoman. Before founding LP Pharmaceutical, Dr. Ye earned her Ph.D. from Osaka University in Japan, conducted post-doctoral research at the University of California, Irvine, and accumulated over two decades of experience as a senior scientist at several U.S. biopharmaceutical companies, specializing in innovative drug development and controlled-release delivery systems. This experience formed the foundation for the company's focus on modified new drugs, a sector with significant growth potential in China.

LP Pharmaceutical’s pipeline targets a range of therapeutic areas such as central nervous system disorders, cardiovascular diseases, and cancer. The company engages in both in-licensing commercial-stage compounds for the Chinese market and out-licensing its own assets to partners in global markets. Its core products include Aripiprazole oral soluble film and Agomelatine oral transmucosal film, among others in various stages of clinical development. While one product, a heart ultrasound contrast agent, has received market approval, its sales have been modest as the company continues to invest heavily in R&D for its broader pipeline. The company operates an international standard GMP industrialization base and is noted as the first formulation company in Fujian province to pass a U.S. FDA on-site inspection.

The company has attracted significant investment from prominent venture capital firms, including Sequoia Capital China, SDIC Innovation, CICC Capital, and Sinolink Securities. It has completed several funding rounds, including a Series B in 2017 for $30 million and a Series C in 2020 for approximately $72.3 million. Despite its strong R&D focus and significant backing, the company has faced financial losses and a canceled IPO attempt on the STAR Market in March 2023.